The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study. Sada A, Foster TR, Al-Ward R, Sawani S, Charchar H, Pishdad R, Ben-Shlomo A, Dy BM, Lyden ML, Bergsland E, Jasim S, Raj N, Shank JB, Hamidi O, Hamrahian AH, Chambô JL, Srougi V, Fragoso MC, Graham PH, Habra MA, Bancos I, McKenzie TJ. Surgery. 2024 01; 175(1):80-89. PMID: 37945477.

Metastatic insulinoma-outcomes in the current era. Masharani U, Lindsay S, Moon F, Paciorek A, Bergsland E. Oncologist. 2024 Oct 30. PMID: 39475415.

Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C.CA Cancer J Clin. 2024 Jul-Aug; 74(4):359-367. PMID: 38685134.

ASO Visual Abstract: Long-term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrie Tumors. Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK. Ann Surg Oncol. 2024 Sep; 31(9):5541-5542. PMID: 38861207.

Burdens of gastroenteropancreatic neuroendocrine neoplasm by diverse race and ethnicities; a rigorous structural equation modeling. Paciorek A, Mulvey C, McKinley M, Zhang L, Cheng I, Moon F, Khuong B, Shih B, Whitman J, Bergsland E. J of the National Comprehensive Cancer Network. 2024. 2025-02, Vol.23 (2), p.27-32.

Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors. Mulvey C,  Paciorek A, Moon F,  Steiding P,  Shih B,  Gubens MA,  Zhang, L, Bergsland EK,  Cheng I. Endocrine-related cancer, 2024-01, Vol.31 (1), p.1, Article 230068.

Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN. JCO Precis Oncol. 2024 Nov; 8:e2400328. PMID: 39509670.

Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors. Endocr Relat Cancer. Mulvey CK, Paciorek A, Moon F, Steiding P, Shih B, Gubens MA, Zhang L, Bergsland EK, Cheng I. 2024 Jan 01; 31(1). PMID: 37882324. PMCID: PMC10762535.

Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53. Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, Kakar S. Endocr Pathol. 2024 Nov 18. PMID: 39556303.

Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. Ann Surg Oncol. Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK. 2024 Sep; 31(9):5507-5514. PMID: 38797790. PMCID: PMC11300575.

The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy. Yadav S, Lawhn-Heath C, Paciorek A, Lindsay S, Mirro R, Bergsland EK, Hope TA. J Nucl Med. 2024 Mar 01; 65(3):409-415. PMID: 38428966.

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. Cancer Res Commun. 2024 Jul 01; 4(7):1793-1801. PMID: 38920407. PMCID: PMC11264598.

Enucleation of Neuroendocrine Liver Metastases. Yogo A, Kasai Y, Nakakura EK. Journal of Gastrointestinal Surgery, 2024-10, Vol.28 (10), p.1735-1737.

ASO Author Reflections: Minimally Invasive Surgery for Prototypical Small Intestinal Neuroendocrine Tumors. Yogo A, Nakakura EK. Annals of surgical oncology, 2024-09, Vol.31 (9), p.5537-5538.

ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer? Miller PN, Nakakura EK. Annals of surgical oncology, 2024-09, Vol.31 (9), p.6203-6204.

Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. Yogo A, Paciorek A, Kasaiy, Moon F, Hirose K, Corvera C, Bergsland E, Nakakura E. Annals of Surgical Oncology, 2024-09, Vol.31 (9).

ASO Visual Abstract: Long-term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. Yogo A, Paciorek A,  Kasai Y,  Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK. Annals of surgical oncology, 2024-09, Vol.31 (9), p.5541-5542.

Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers. Kong G, Noe G, Chiang C, Herrmann K, Hope TA, Michael M. Journal of neuroendocrinology, 2024-11, p.e13461.

Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy. Strosberg J, Hofman MS,  Al-Toubah T, Hope TA. Journal of Nuclear Medicine, 2024-03, Vol.65 (3), p.362-36.

Technical note: Errors introduced when using Dose Voxel Kernels for estimating absorbed dose from radiopharmaceutical therapies involving alpha emitters. Tranel J, Palm S, Feng FY,  St. James S, Hope TA. Medical physics (Lancaster), 2024-08, Vol.51 (8), p.5764-5772.

The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy. Yadav S, Lawhn-Heath C, Paciorek A, Lindsay S, Mirro R,  Bergsland EK, Hope TA. Journal of Nuclear Medicine, 2024-03, Vol.65 (3), p.409-415.

Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. Chauhan A, Chan K, Halfdanarson TR,  Bellizzi AM,  Rindi G,  O’Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. CA: a cancer journal for clinicians, 2024-07, Vol.74 (4), p.359-367.

Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, Eiber M, Barbato F, Moon D, Counter W, John N,  Xue A, Franklin A, Thompson J, Rasiah K, Frydenberg M, Yaxley J, Buteau J, Agrawal S, Ho B, Nguyen A, Liu V, Lee J, Woo H, Hsiao E, Sutherland T, Perry E, Stricker P, Hofman MS, Kasivisvanathan V, Roberts M,  Murphy D. The Journal of Urology, 2024-08, Vol.212 (2), p.299-309.

Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A,  Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. European urology, 2024-06, Vol.85 (6), p.511-516.

Low- and high-volume disease in mHSPC, from CHAARTED to PSMA-PET: An international multicenter retrospective study. Unterrainer L, Hope TA, Fendler WP, Ndlovu H, Barbato F, Sathekge M, Herrmann K, Czernin J, Calais J. Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.44-44.

Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy. Yadav S, Lowery B, Tuchayi AM, Jiang F, Saelee R, Aggarwal RR, Juarez R, Flavell RR, Hope TA. The Journal of nuclear medicine (1978), 2024-09, Vol.65 (9), p.1395.

Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma. Kohlbrenner R, Wu X, Nguyen HG, Cooperberg MR, Chakravarty T, Carroll PR, Hope TA. Radiology, 2024-08, Vol.312 (2)

Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. Del Rivero, J., Mailman, J., Rabow, M. W., Chan, J. A., Creed, S., Kennecke, H. F., Pasieka, J., Zuar, J., Singh, S., and Fishbein, L. (2023).  Endocrine-Related Cancer 30, 7, e220226, https://doi.org/10.1530/ERC-22-0226.